Novel properties of phenanthroline‐amine include binding to amyloid plaques and suppressing plaque growth in APP/PS1 mouse model of Alzheimer’s disease (AD)

Our study confirmed that chronic oral dosing with PAA resulted in plaque reductions comparable to that seen in the original study that used a smaller number of a less common mouse model of AD. This study also showed that PAA is capable of binding directly to amyloid plaques. Possible endogenous target molecules, based on the chemical properties of PAA, include certain transition metals, certain glycosylated molecules of AD relevance (APOE, NCAM1, APP and gangliosides) and metalloproteases.